Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Mar 19, 2015 10:35am
213 Views
Post# 23538121

Since We Are Talking About Being Corrected

Since We Are Talking About Being CorrectedIn the interest of accuracy, I'll correct myself on something I was talking about a few days ago.

A few days ago I was criticizing the PSCK9 touting companies for the fact that their RRR was (probably) lower than our RRR (reletive risk reduction of course).

Toinv261 was kind enough to politely let me know privately that (not his words - mine), I was not making any sense with that point.  He was more polite that I am being here. The reason is that the risks are reletive and the groups being targeted in the studies are different.

Duh!!!  

When I thought it through, this of course makes perfect sense.  Apples and oranges were being compared by me, even though in both cases it was MACE they were trying to lower.   That's the part that through me off - I focused on the commonality of MACE and assumed the groups were the same.   (The groups in the study were obviously not the same, since they each had a very different level of MACE events...)

Of course, this honest but silly misake only shows my lack of a science background, so I'm sorry to have to correct myself here.  But I value accuracy over protecting my ego.  (Sorry ego!)

I guess this is a good reminder for us non-scientific, non-mathmetician types to be very careful with this stuff.  It's easy to make mistakes and come to the wrong conclusion!   And always good to get good advice from those who know more.   Thanks Toinv261!  

GLTA








Bullboard Posts